Baudax Bio Announces Proposed Public Offering of Securities
February 24 2022 - 4:40PM
Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a
pharmaceutical company focused on commercializing and developing
innovative products for acute care settings, announced it has
commenced a proposed underwritten public offering of shares of
common stock (or common stock equivalents), together with warrants
to purchase its shares of common stock (the “Offering”). In
addition, the Company intends to grant the underwriter an option to
purchase additional shares and/or warrants at the public offering
price, less the underwriting discounts and commissions. All of the
shares of common stock (or common stock equivalents) and warrants
to be sold in the Offering are to be offered by the Company. The
Offering is subject to market and other conditions, and there can
be no assurance as to whether or when the Offering may be
completed, or as to the actual size or terms of the Offering.
The Company currently intends to use the net
proceeds from this offering for the commercialization of ANJESO,
pipeline development activities, and general corporate
purposes.
H.C. Wainwright & Co. is acting as the sole
book running manager for the proposed Offering.
The securities described above are being offered
pursuant to an effective “shelf” registration statement (File No.
333-253117) that was filed with the Securities and Exchange
Commission (the “SEC”) and was declared effective by the SEC on
September 2, 2021. The securities may be offered only by means of a
prospectus supplement and an accompanying base prospectus. A
preliminary prospectus supplement and accompanying prospectus
describing the terms of the proposed Offering has been filed with
the SEC. A copy of the preliminary prospectus supplement and
accompanying prospectus relating to the Offering is available on
the SEC’s website located at http://www.sec.gov and may also be
obtained by contacting H.C. Wainwright & Co., LLC, 430 Park
Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or
emailing placements@hcwco.com.
This news release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on commercializing and developing innovative products for acute
care settings. ANJESO is the first and only 24-hour, intravenous
(IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for
the management of moderate to severe pain. In addition to ANJESO,
Baudax Bio has a pipeline of other innovative pharmaceutical assets
including two novel neuromuscular blocking agents (NMBs) and a
proprietary chemical reversal agent specific to these NMBs. For
more information, please visit www.baudaxbio.com.
Forward Looking Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Baudax Bio’s expectations about
its future performance and opportunities that involve substantial
risks and uncertainties. When used herein, the words “anticipate,”
“believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,”
“intend” and “expect” and similar expressions, as they relate to
Baudax Bio or its management, are intended to identify such
forward-looking statements. Forward-looking statements may include,
without limitation, statements regarding market conditions, the
completion of the proposed offering and the intended use of net
proceeds from the proposed offering. These forward-looking
statements are based on information available to Baudax Bio as of
the date of publication on this internet site and are subject to a
number of risks, uncertainties, and other factors that could cause
Baudax Bio’s performance to differ materially from those expressed
in, or implied by, these forward-looking statements, including, but
not limited risks associated with market and other conditions.
Baudax Bio assumes no obligation to update any such forward-looking
statements. These forward-looking statements should be considered
together with the risks and uncertainties that may affect our
business and future results included in our filings with the
Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are based on information currently
available to us, and we assume no obligation to update any
forward-looking statements except as required by applicable law.
These forward looking statements should be considered together with
the risks and uncertainties that may affect Baudax Bio’s business
and future results included in Baudax Bio’s filings with the
Securities and Exchange Commission at www.sec.gov.
Contact: Argot Partners Sam
Martin / Kaela Ilami (212) 600-1902 baudaxbio@argotpartners.com
Media Contact: Argot Partners
David Rosen (212) 600-1902 david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024